BR112015016466A2 - método para o tratamento de câncer baseado no estado de mutação de k-ras - Google Patents
método para o tratamento de câncer baseado no estado de mutação de k-rasInfo
- Publication number
- BR112015016466A2 BR112015016466A2 BR112015016466A BR112015016466A BR112015016466A2 BR 112015016466 A2 BR112015016466 A2 BR 112015016466A2 BR 112015016466 A BR112015016466 A BR 112015016466A BR 112015016466 A BR112015016466 A BR 112015016466A BR 112015016466 A2 BR112015016466 A2 BR 112015016466A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment method
- mutation state
- cancer treatment
- ras mutation
- based cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000035772 mutation Effects 0.000 title abstract 3
- 101710113436 GTPase KRas Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361848793P | 2013-01-11 | 2013-01-11 | |
| US201361752417P | 2013-01-14 | 2013-01-14 | |
| US13/794,712 US20140199405A1 (en) | 2013-01-11 | 2013-03-11 | Method for treating cancer based on mutation status of k-ras |
| PCT/US2014/011097 WO2014110408A1 (en) | 2013-01-11 | 2014-01-10 | Method for treating cancer based on mutation status of k-ras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015016466A2 true BR112015016466A2 (pt) | 2017-07-11 |
Family
ID=51165319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015016466A BR112015016466A2 (pt) | 2013-01-11 | 2014-01-10 | método para o tratamento de câncer baseado no estado de mutação de k-ras |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140199405A1 (enExample) |
| EP (1) | EP2943184A4 (enExample) |
| JP (1) | JP2016506908A (enExample) |
| KR (1) | KR20150103746A (enExample) |
| AU (1) | AU2014205254A1 (enExample) |
| BR (1) | BR112015016466A2 (enExample) |
| CA (1) | CA2897581A1 (enExample) |
| HK (1) | HK1217292A1 (enExample) |
| IL (1) | IL239740A0 (enExample) |
| MX (1) | MX2015008889A (enExample) |
| WO (1) | WO2014110408A1 (enExample) |
| ZA (1) | ZA201504878B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE042678T2 (hu) | 2005-08-31 | 2019-07-29 | Abraxis Bioscience Llc | Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek |
| EP2949763A3 (en) | 2006-08-11 | 2016-03-09 | Johns Hopkins University | Consensus coding sequences of human breast cancers |
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス， エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
| HRP20160609T1 (hr) | 2010-03-26 | 2016-09-23 | Abraxis Bioscience, Llc | Postupci liječenja hepatocelularnog karcinoma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| KR101970342B1 (ko) | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| US9775892B2 (en) | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
| CN106414493A (zh) | 2014-05-06 | 2017-02-15 | 塔格瓦克斯公司 | 包含突变的ras肽和化疗剂的肽疫苗 |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| WO2018067943A1 (en) * | 2016-10-07 | 2018-04-12 | Abraxis Bioscience, Llc | Methods of treating biliary tract cancer |
| EP3444272A1 (en) * | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Treatment of ck8 positive cancers in relation with k-ras gene status |
| EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
| EP4051241A4 (en) | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
| EP4146346A4 (en) * | 2020-05-08 | 2025-05-14 | Cardiff Oncology, Inc. | Methods of monitoring kras mutations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG166775A1 (en) * | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| WO2007001868A1 (en) * | 2005-06-28 | 2007-01-04 | Genentech, Inc. | Egfr and kras mutations |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| HRP20140360T4 (hr) * | 2007-03-13 | 2022-06-10 | Amgen, Inc. | K-ras mutacije i terapija anti-egfr antitijelom |
| WO2011116181A1 (en) * | 2010-03-17 | 2011-09-22 | Caris Life Sciences, Inc. | Theranostic and diagnostic methods using sparc and hsp90 |
| SG178873A1 (en) * | 2009-08-25 | 2012-04-27 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| KR101894689B1 (ko) * | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2795776A1 (en) * | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| AU2011255438A1 (en) * | 2010-05-20 | 2013-01-10 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| US9945862B2 (en) * | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| WO2013134786A2 (en) * | 2012-03-09 | 2013-09-12 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarker compositions and methods |
| AU2013201584A1 (en) * | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
-
2013
- 2013-03-11 US US13/794,712 patent/US20140199405A1/en not_active Abandoned
-
2014
- 2014-01-10 JP JP2015552819A patent/JP2016506908A/ja active Pending
- 2014-01-10 KR KR1020157021321A patent/KR20150103746A/ko not_active Withdrawn
- 2014-01-10 BR BR112015016466A patent/BR112015016466A2/pt not_active Application Discontinuation
- 2014-01-10 CA CA2897581A patent/CA2897581A1/en not_active Abandoned
- 2014-01-10 HK HK16105270.2A patent/HK1217292A1/zh unknown
- 2014-01-10 EP EP14738060.4A patent/EP2943184A4/en not_active Withdrawn
- 2014-01-10 AU AU2014205254A patent/AU2014205254A1/en not_active Abandoned
- 2014-01-10 MX MX2015008889A patent/MX2015008889A/es unknown
- 2014-01-10 WO PCT/US2014/011097 patent/WO2014110408A1/en not_active Ceased
-
2015
- 2015-07-01 IL IL239740A patent/IL239740A0/en unknown
- 2015-07-07 ZA ZA2015/04878A patent/ZA201504878B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150103746A (ko) | 2015-09-11 |
| JP2016506908A (ja) | 2016-03-07 |
| ZA201504878B (en) | 2016-10-26 |
| US20140199405A1 (en) | 2014-07-17 |
| AU2014205254A1 (en) | 2015-07-23 |
| CA2897581A1 (en) | 2014-07-17 |
| IL239740A0 (en) | 2015-08-31 |
| EP2943184A4 (en) | 2016-07-20 |
| HK1217292A1 (zh) | 2017-01-06 |
| WO2014110408A1 (en) | 2014-07-17 |
| MX2015008889A (es) | 2015-11-13 |
| EP2943184A1 (en) | 2015-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015016466A2 (pt) | método para o tratamento de câncer baseado no estado de mutação de k-ras | |
| BR112017028132A2 (pt) | métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula | |
| BR112012024442A2 (pt) | métodos de tratamento de câncer | |
| CL2017003457A1 (es) | Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor. | |
| MX370662B (es) | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. | |
| BR112012024349A2 (pt) | métodos de tratamento de carcinoma hepatocelular | |
| BR112017027954A2 (pt) | métodos de tratamento de tumores de célula epitelioide | |
| MX2015008888A (es) | Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. | |
| BR112015022047A2 (pt) | métodos para tratar câncer de bexiga | |
| NI201200179A (es) | Métodos de tratamiento contra el cáncer pancreático | |
| BR112015021970A2 (pt) | composições à base de nanopartículas | |
| BR112012030699A2 (pt) | métodos para tratar câncer de bexiga | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
| BR112015016681A2 (pt) | métodos de tratamento de câncer pancreático | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX389962B (es) | Metodos para tratar trastornos mitocondriales y metabolicos. | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| BR112015032758A2 (pt) | nanopartículas poliméricas de docetaxel para o tratamento de câncer | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| ZA202000375B (en) | Compounds for the prevention and treatment of medical disorders and uses thereof | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112019006329A2 (pt) | métodos de tratamento de câncer do trato biliar | |
| BR112015022196A2 (pt) | composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos | |
| BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |